B2065
/ Tasly
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 29, 2026
A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke.
(clinicaltrials.gov)
- P1/2 | N=54 | Recruiting | Sponsor: Tasly Pharmaceutical Group Co., Ltd
New P1/2 trial • Cardiovascular • Ischemic stroke
1 to 1
Of
1
Go to page
1